Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2026-02-21 @ 6:24 AM
Study NCT ID:
NCT02920892
Status:
COMPLETED
Last Update Posted:
2023-10-10
First Post:
2016-09-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
AFQ056 for Language Learning in Children With FXS
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-06-29', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D005600', 'term': 'Fragile X Syndrome'}], 'ancestors': [{'id': 'D038901', 'term': 'X-Linked Intellectual Disability'}, {'id': 'D008607', 'term': 'Intellectual Disability'}, {'id': 'D019954', 'term': 'Neurobehavioral Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D025064', 'term': 'Sex Chromosome Disorders'}, {'id': 'D025063', 'term': 'Chromosome Disorders'}, {'id': 'D000013', 'term': 'Congenital Abnormalities'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D040181', 'term': 'Genetic Diseases, X-Linked'}, {'id': 'D020271', 'term': 'Heredodegenerative Disorders, Nervous System'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C581397', 'term': 'mavoglurant'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'Elizabeth_Berry-Kravis@rush.edu', 'phone': '312-942-4036', 'title': 'Elizabeth Berry-Kravis, MD PhD', 'organization': 'Rush University Medical Center'}, 'certainAgreement': {'restrictionType': 'LTE60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': "Participants were monitored for AEs from the time they signed the consent until the final Study visit, up to 21 months. If an AE was ongoing or discovered at a subject's final Study visit, the AE was followed until resolution, or for a minimum of 30 days, whichever comes first.", 'description': "Adverse event review were done at all study visits, and during dose titration reviews. Safety monitoring was based on close observation of the child by the family. Children in the proposed age range who have developmental delay with a mental age of approximately 1-5 years are not be able to spontaneously communicate all (if any) side effects. Therefore, adverse event information was collected by querying caregivers about any differences in the child's behavior or wellbeing.", 'eventGroups': [{'id': 'EG000', 'title': 'Placebo Lead-In Period', 'description': 'Children with FXS were seen for a screening visit and if they met entry criteria, they began a single-blind 4-month placebo lead-in period prior to randomization during which they received their therapy treatments as usual, with no language intervention.', 'otherNumAtRisk': 110, 'deathsNumAtRisk': 110, 'otherNumAffected': 65, 'seriousNumAtRisk': 110, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Double-Blind Period: Placebo With Language Intervention', 'description': 'Double-Blind Placebo Period: After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive a placebo suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, dose titration to maximum tolerated dose of matching placebo occurred over 7 weeks. After 7 weeks, the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on placebo for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.', 'otherNumAtRisk': 49, 'deathsNumAtRisk': 49, 'otherNumAffected': 44, 'seriousNumAtRisk': 49, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Double-Blind Period: AFQ056 With Language Intervention', 'description': 'Double-Blind Placebo Period: After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive AFQ056 suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, subjects in the AFQ056 treatment group began with a dose of 25 mg AFQ056 twice per day and titrated to their maximum tolerated dose over the course of 7 weeks. After 7 weeks the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on a stable dose of AFQ056 (ranging from 12.5 mg BID to 100 mg BID), for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.', 'otherNumAtRisk': 50, 'deathsNumAtRisk': 50, 'otherNumAffected': 45, 'seriousNumAtRisk': 50, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Open-Label Period: AFQ056 With Language Intervention', 'description': "After 8 months of treatment in the placebo-controlled phase, all subjects had assessments completed and were given the opportunity to enter the open-label extension (OLE) in which all subjects received AFQ056. The OLE began with 2 months of flexible dose titration to each subject's maximum tolerated dose followed by a period of stable treatment. Subjects also continued the language intervention through the extension phase.\n\nThe total duration of the OLE depended on when the subject was enrolled into the study and ranged from no open label to 8 months.\n\nThe OLE included 46 patients who were previously assigned to placebo and 43 patients who were previously assigned to AFQ056.", 'otherNumAtRisk': 89, 'deathsNumAtRisk': 89, 'otherNumAffected': 76, 'seriousNumAtRisk': 89, 'deathsNumAffected': 0, 'seriousNumAffected': 1}], 'otherEvents': [{'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 13, 'numAffected': 10}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 16, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 7, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 17, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 6, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 12, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 7, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Otitis Media', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 11, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 11, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pharyngitis Streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 24, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 23, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 37, 'numAffected': 22}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 55, 'numAffected': 41}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Psychomotor Hyperactivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 30, 'numAffected': 25}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Sensory Processing Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Aggression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 8, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Agitation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 11, 'numAffected': 10}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Attention Deficit Hyperactivity Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 14, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 19, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 20, 'numAffected': 18}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 17, 'numAffected': 13}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Perseveration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Sleep Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Atypical Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Croup Infectious', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 110, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 49, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 50, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 89, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change in Weighted Child Intentional Communication Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.14', 'groupId': 'OG000', 'lowerLimit': '0.05', 'upperLimit': '0.22'}, {'value': '0.04', 'groupId': 'OG001', 'lowerLimit': '-0.05', 'upperLimit': '0.12'}]}]}], 'analyses': [{'pValue': '0.1587', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Slope', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '-0.1', 'ciLowerLimit': '-0.22', 'ciUpperLimit': '0.02', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline through Month 8', 'description': 'The Weighted Child Intentional Communication Score is derived from a 22 minute semi-structured examiner/child play session. Structured and unstructured component scores are found by multiplying each intentional communication act by the following weights: nonverbal = 1; single symbol = 2; and multiple symbols = 3. The two scores are summed together to obtain the total. Higher scores indicate more child-initiated communication. There is no maximum score.\n\nThe scale was administered at Baseline, Month 2, Month 4, Month 6, and Month 8. A composite score representing the average of the estimated change scores calculated at months 2, 4, 6, and 8 was recorded. A higher least squares mean value indicates a greater increase in WCS score from baseline.', 'unitOfMeasure': 'log10(scores on a scale)', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Comparison of WCS from baseline and from month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'Change in Mullen Scales of Early Learning (MSEL) Developmental Quotient (DQ)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.7', 'groupId': 'OG000', 'lowerLimit': '-1.90', 'upperLimit': '0.50'}, {'value': '-2.35', 'groupId': 'OG001', 'lowerLimit': '-3.55', 'upperLimit': '-1.16'}]}]}], 'analyses': [{'pValue': '0.1054', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Slope', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '-1.66', 'ciLowerLimit': '-3.34', 'ciUpperLimit': '0.03', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline through Month 8', 'description': 'Mullen Scales of Early Learning (MSEL) Developmental Quotient (DQ) is calculated by averaging the developmental age equivalents from 4 domains of the Mullen (visual reception, fine motor, receptive language, and expressive language) to find developmental age in months, dividing by chronological age in months, then multiplying by 100. DQ can range from 1 to 70. A higher DQ indicates better performance on the MSEL.\n\nThe MSEL was administered at Baseline, Month 2, and Month 8. A composite score representing the average of the estimated change scores calculated at month 2 and month 8 was recorded. A negative least squares mean indicates a net decrease in DQs over time. A more negative least squares mean indicates a larger negative change in DQs over time.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Comparison of DQ from baseline and from month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'Change in Mullen Scales of Early Learning (MSEL) Expressive Language Subscore', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.99', 'groupId': 'OG000', 'lowerLimit': '1.19', 'upperLimit': '2.79'}, {'value': '1.32', 'groupId': 'OG001', 'lowerLimit': '0.52', 'upperLimit': '2.11'}]}]}], 'analyses': [{'pValue': '0.32', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Slope', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '-0.67', 'ciLowerLimit': '-1.79', 'ciUpperLimit': '0.45', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline through Month 8', 'description': 'The MSEL measures performance over 5 subscales including expressive language. The range of possible subscores for the expressive language domain is 1-50. A higher score indicates better performance / greater use of expressive language\n\nThe MSEL was administered at Baseline, Month 2, and Month 8. A composite score representing the average of the estimated change scores calculated at month 2 and month 8 was recorded. A positive least squares mean indicates a net positive change in expressive language scores over time. A higher least squares mean indicates a larger change in expressive language scores over time.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Comparison of MSEL expressive language subscore from baseline and from month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'Change in Vineland Adaptive Behavior Scale (Vineland-3) Composite Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.68', 'groupId': 'OG000', 'lowerLimit': '-0.51', 'upperLimit': '1.88'}, {'value': '0.39', 'groupId': 'OG001', 'lowerLimit': '-0.81', 'upperLimit': '1.60'}]}]}], 'analyses': [{'pValue': '0.78', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Slope', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '-0.29', 'ciLowerLimit': '-1.98', 'ciUpperLimit': '1.4', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline through Month 8', 'description': "The Vineland-3 composite score is yielded from the subject's level of adaptive functioning in the domains of communication, daily living skills, socialization, and motor skills. The range of possible composite scores is 20-140 with a higher score indicating higher levels of adaptive functioning.\n\nThe Vineland-3 was administered at Baseline, Month 2, Month 4, Month 6, and Month 8. A composite score representing the average of the estimated change scores calculated at months 2, 4, 6, and 8 was recorded. A positive least squares mean indicates a net increase in composite score over time. A higher least squares mean indicates a greater change in composite score over time.", 'unitOfMeasure': 'scores on a scale', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Comparison of Vineland-3 Composite Score from baseline and from month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'Change in Vineland Adaptive Behavior Scale (Vineland-3) Communication Subscore', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.54', 'groupId': 'OG000', 'lowerLimit': '-0.97', 'upperLimit': '2.05'}, {'value': '0.63', 'groupId': 'OG001', 'lowerLimit': '-0.90', 'upperLimit': '2.16'}]}]}], 'analyses': [{'pValue': '0.94', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Slope', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.1', 'ciLowerLimit': '-2.05', 'ciUpperLimit': '2.24', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Month 8', 'description': 'The communication domain of the Vineland-3 examines adaptive functioning in receptive, expressive, and written language. The range of possible subscores for the communication domain is 20-140 with a higher score indicating more advanced use of language.\n\nThe Vineland-3 was administered at Baseline, Month 2, Month 4, Month 6, and Month 8. A composite score representing the average of the estimated change scores calculated at months 2, 4, 6, and 8 was recorded. A positive least squares mean indicates a net increase in communication score over time. A higher least squares mean indicates a greater change in communication score over time.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Comparison of Vineland-3 Communication Subscore from baseline and from month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'Change in Preschool Language Scale (PLS-5) Expressive Communication Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.78', 'groupId': 'OG000', 'lowerLimit': '1.10', 'upperLimit': '2.46'}, {'value': '0.93', 'groupId': 'OG001', 'lowerLimit': '0.25', 'upperLimit': '1.60'}]}]}], 'analyses': [{'pValue': '0.1428', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Slope', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '-0.85', 'ciLowerLimit': '-1.81', 'ciUpperLimit': '0.11', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Month 8', 'description': 'The PLS-5 is a comprehensive developmental language assessment that requires the child to point to or verbally respond to items. Raw scores for expressive language were collected from this test. It is difficult to specify an upper bound on the score, because there is no clear expectation of a limit on the number of times a child can communicate unless one sets it artificially (e.g., once per second in an 11-minute free play). The lower bound is zero for a child who produces no communication acts.\n\nThe PLS-5 was administered at Baseline, Month 2, and Month 8. A composite score representing the average of the estimated change scores calculated at month 2 and month 8 was recorded. A higher least squares mean indicates a larger change in PLS-5 communication score over 8 months.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Comparison of PLS-5 expressive communication scores from baseline and from month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'MacArthur-Bates Communicative Development Inventory (CDI) Number of Spoken Words', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '319', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '677'}, {'value': '413.5', 'groupId': 'OG001', 'lowerLimit': '0', 'upperLimit': '680'}]}]}], 'analyses': [{'pValue': '0.24', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.9462', 'ciLowerLimit': '0.8764', 'ciUpperLimit': '1.0215', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEDIAN', 'timeFrame': 'Month 8', 'description': 'The MacArthur-Bates CDI is a parent interview that allows tracking of a child\'s progress in developing words, sentences, and more complex language. The assessment consists of two parts including "Words Children Use," a 680-word vocabulary checklist in which the parent indicates those vocabulary words the child regularly produces in spoken language, and "Sentences and Grammar" an assessment of several aspects of grammar and word endings. The MacArthur-Bates CDI number of spoken words will be recorded with higher scores indicating more words used / greater language development at Month 8.', 'unitOfMeasure': 'Spoken Words', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Number of words spoken at month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With a Positive Response as Defined by Improvement in Clinical Global Impression - Improvement (CGI-I) Overall Function Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'Randomized to receive AFQ056-matched placebo twice per day in conjunction with the language intervention during the double-blind period.'}, {'id': 'OG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'Randomized to receive AFQ056 twice per day in conjunction with the language intervention during the double-blind period. Subjects will take between 25-100 mg BID orally. Dose will depend on individual patient max tolerance.'}], 'classes': [{'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.92', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.95', 'ciLowerLimit': '0.4', 'ciUpperLimit': '2.27', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Month 8', 'description': "Completion of the CGI-I requires the clinician to rate how much the study participant's illness has improved or worsened relative to a baseline state. For this study, two sets of CGI-I are administered at each applicable visit - one associated with Language/Communication and the other to Overall Function. The Overall Function CGI-I considers all areas of function including cognition, adaptive behavior, and maladaptive behavior. The CGI-I is a 7-point scale that includes the following ratings: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.\n\nThe CGI-I was rated at all study visits after screening. This measure shows the number of participants with positive CGI-I scores indicating perceived improvement at Month 8.", 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with positive change in CGI-I scores from baseline to month 8 visit (end of double-blind period) in both AFQ056 \\& Language Intervention and Placebo \\& Language Intervention groups.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo Lead-In', 'description': 'Children with FXS were seen for a screening visit and if they met entry criteria, they began a single-blind 4-month placebo lead-in period prior to randomization during which they received their therapy treatments as usual, with no language intervention.'}, {'id': 'FG001', 'title': 'Double-Blind Placebo, Then Open-Label AFQ056', 'description': "Double-Blind Placebo Period: After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive a placebo suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, dose titration to maximum tolerated dose of matching placebo occurred over 7 weeks. After 7 weeks, the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on placebo for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.\n\nOpen-Label Period: After 8 months of treatment in the placebo-controlled phase, all subjects had assessments completed and were given the opportunity to enter the open-label extension (OLE) in which all subjects received AFQ056. The OLE began with 2 months of flexible dose titration to each subject's maximum tolerated dose followed by a period of stable treatment. Subjects also continued the language intervention through the extension phase.\n\nThe total duration of the OLE depended on when the subject was enrolled into the study and ranged from no open label to 8 months."}, {'id': 'FG002', 'title': 'Double-Blind AFQ056, Then Open-Label AFQ056', 'description': "Double-Blind Placebo Period: After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive AFQ056 suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, subjects in the AFQ056 treatment group began with a dose of 25 mg AFQ056 twice per day and titrated to their maximum tolerated dose over the course of 7 weeks. After 7 weeks the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on a stable dose of AFQ056 (ranging from 12.5 mg BID to 100 mg BID), for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.\n\nOpen-Label Period: After 8 months of treatment in the placebo-controlled phase, all subjects had assessments completed and were given the opportunity to enter the open-label extension (OLE) in which all subjects received AFQ056. The OLE began with 2 months of flexible dose titration to each subject's maximum tolerated dose followed by a period of stable treatment. Subjects also continued the language intervention through the extension phase.\n\nThe total duration of the OLE depended on when the subject was enrolled into the study and ranged from no open label to 8 months."}], 'periods': [{'title': 'Placebo Lead-In Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '110'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '99'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '11'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Subject Ineligible', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Subject Screen Fail', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}, {'title': 'Placebo-Controlled Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '49'}, {'groupId': 'FG002', 'numSubjects': '50'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '46'}, {'groupId': 'FG002', 'numSubjects': '43'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '7'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '5'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}]}, {'title': 'Open-Label Extension (OLE) Period', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '46'}, {'groupId': 'FG002', 'numSubjects': '43'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '37'}, {'groupId': 'FG002', 'numSubjects': '39'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Study Drug Expiration', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'It is expected that recruitment/enrollment will occur over 18 months. Enrollment must end at the end of February 2020 due to study drug expiration at the end of August 2021.', 'preAssignmentDetails': 'Prior to randomization, there will be a 4-month single-blind placebo lead in after screening assessments during which subjects will have therapy treatments as usual to control for the effects of the language intervention. The placebo lead-in will also control for placebo effects which are prominent in clinical trials in FXS.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'BG000'}, {'value': '50', 'groupId': 'BG001'}, {'value': '99', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo Comparator: Double-Blind Placebo With Language Intervention', 'description': 'After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive a placebo suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, dose titration to maximum tolerated dose of matching placebo occurred over 7 weeks. After 7 weeks, the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on placebo for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.'}, {'id': 'BG001', 'title': 'Experimental: Double-Blind AFQ056 With Language Intervention', 'description': 'After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive AFQ056 suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, subjects in the AFQ056 treatment group began with a dose of 25 mg AFQ056 twice per day and titrated to their maximum tolerated dose over the course of 7 weeks. After 7 weeks the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on a stable dose of AFQ056 (ranging from 12.5 mg BID to 100 mg BID), for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '5.1', 'spread': '1.4', 'groupId': 'BG000'}, {'value': '5.3', 'spread': '1.3', 'groupId': 'BG001'}, {'value': '5.2', 'spread': '1.4', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '42', 'groupId': 'BG000'}, {'value': '46', 'groupId': 'BG001'}, {'value': '88', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '42', 'groupId': 'BG001'}, {'value': '85', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '84', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '50', 'groupId': 'BG001'}, {'value': '97', 'groupId': 'BG002'}]}]}, {'title': 'China', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Weighted Child Intentional Communication Score', 'classes': [{'categories': [{'measurements': [{'value': '282.8', 'spread': '264.2', 'groupId': 'BG000'}, {'value': '304.0', 'spread': '270.2', 'groupId': 'BG001'}, {'value': '293.2', 'spread': '266.0', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': "The Weighted Child Intentional Communication Score is coded from a 22 minute semi-structured examiner/child play session. The score reflects child initiated communication that involves the child's use of gestures, eye contact, vocalizations, and/or words and word combinations to communicate a message to a listener. Higher scores indicate more child-initiated communication. There is no maximum score.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Mullen Scales of Early Learning (MSEL) Developmental Quotient (DQ)', 'classes': [{'categories': [{'measurements': [{'value': '45.4', 'spread': '14.4', 'groupId': 'BG000'}, {'value': '43.9', 'spread': '16.3', 'groupId': 'BG001'}, {'value': '44.6', 'spread': '15.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The MSEL measures performance over 5 subscales: gross motor, fine motor, visual reception, expressive language, and receptive language. Developmental age can be calculated by averaging the developmental age equivalents from 4 domains of the Mullen (visual reception, fine motor, receptive language, and expressive language). To calculate the developmental quotient (DQ), developmental age in months is divided by chronological age in months and multiplied by 100. DQ values can range from 1 to 70. A higher DQ indicates better performance on the MSEL.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Mullen Scales of Early Learning (MSEL) Expressive Language Subscore', 'classes': [{'categories': [{'measurements': [{'value': '22.5', 'spread': '10.0', 'groupId': 'BG000'}, {'value': '23.2', 'spread': '10.7', 'groupId': 'BG001'}, {'value': '22.9', 'spread': '10.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The MSEL measures performance over 5 subscales including expressive language. The range of possible subscores for the expressive language domain is 1-50. A higher score indicates better performance / greater use of expressive language.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Vineland Adaptive Behavior Scale (Vineland-3) Composite Score', 'classes': [{'categories': [{'measurements': [{'value': '66.0', 'spread': '10.3', 'groupId': 'BG000'}, {'value': '64.0', 'spread': '12.2', 'groupId': 'BG001'}, {'value': '65.0', 'spread': '11.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The Vineland-3 is an informant-based measure that is administered using a semi-structured interview format. The assessment provides standard scores in domains of communication, daily living skills, socialization, and motor skills. The Adaptive Behavior Composite (ABC) is yielded from these domain scores and provides an overall summary measure of adaptive functioning.The range of possible composite scores is 20-140 with a higher score indicating higher levels of adaptive functioning.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Vineland Adaptive Behavior Scale (Vineland-3) Communication Score', 'classes': [{'categories': [{'measurements': [{'value': '61.2', 'spread': '15.4', 'groupId': 'BG000'}, {'value': '56.8', 'spread': '19.1', 'groupId': 'BG001'}, {'value': '59.0', 'spread': '17.4', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The communication domain of the Vineland-3 examines adaptive functioning in receptive, expressive, and written language.The range of possible subscores for the communication domain is 20-140 with a higher score indicating more advanced use of language.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Preschool Language Scale (PLS-5) Expressive Communication Score', 'classes': [{'categories': [{'measurements': [{'value': '28.8', 'spread': '9.9', 'groupId': 'BG000'}, {'value': '29.7', 'spread': '10.7', 'groupId': 'BG001'}, {'value': '29.2', 'spread': '10.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The PLS-5 is a comprehensive developmental language assessment that requires the child to point to or verbally respond to items. One domain that is evaluated using this assessment is expressive language. Higher scores represent greater use of expressive communication. It is difficult to specify an upper bound on the score, because there is no clear expectation of a limit on the number of times a child can communicate unless one sets it artificially (e.g., once per second in an 11-minute free play). The lower bound is zero for a child who produces no communication acts.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'MacArthur-Bates Communicative Development Inventory (CDI) Number of Spoken Words', 'classes': [{'categories': [{'measurements': [{'value': '262.8', 'spread': '231.4', 'groupId': 'BG000'}, {'value': '305.6', 'spread': '253.3', 'groupId': 'BG001'}, {'value': '284.2', 'spread': '242.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The MacArthur-Bates CDI is a parent interview that allows tracking of a child\'s progress in developing words, sentences, and more complex language. The assessment consists of two parts including "Words Children Use," a 680-word vocabulary checklist in which the parent indicates those vocabulary words the child regularly produces in spoken language, and "Sentences and Grammar" an assessment of several aspects of grammar and word endings. The MacArthur-Bates CDI number of spoken words (raw scale) will be recorded with higher scores indicating more words used / greater language development.', 'unitOfMeasure': 'words', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Clinical Global Impression - Improvement: Overall Function', 'classes': [{'title': 'Much/very much improved', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}]}]}, {'title': 'Minimally improved', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}]}]}, {'title': 'No change', 'categories': [{'measurements': [{'value': '37', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '72', 'groupId': 'BG002'}]}]}, {'title': 'Minimally worse', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}, {'title': 'Much/very much worse', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "The Overall Function CGI-I considers all areas of function including cognition, adaptive behavior, and maladaptive behavior and requires the clinician to rate how much the study participant's overall function has improved or worsened relative to a baseline state. The CGI-I is a 7-point scale that ranges from very much improved (1) to very much worse (7).\n\nThe CGI-I at baseline was completed relative to overall function at screening.", 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-02-03', 'size': 2531739, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2023-06-09T15:22', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': 'After screening assessments, participants who met entry criteria and agreed to participate entered a single-blind 4-month placebo lead-in during which study participants had therapy treatments as usual to control for the effects of the language intervention. The 4-month placebo lead-in allowed for placebo effects to stabilize.\n\nAt the end of the 4-month placebo lead-in, all participants will enter a double blind placebo controlled phase in which they will have a repeat battery of AFQ056 baseline assessments and will be randomized 1:1 to AFQ056 or placebo. Both treatment groups received an intensive language intervention for 6 months after 2 months of flexible dose titration to establish their maximum tolerated dose (MTD).\n\nAfter 8 months of treatment in the placebo-controlled phase (including 6 months of language intervention), all participants had final assessments and entered the open label extension (OLE) of about 8 months.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The trial will use a double-blind placebo-controlled parallel-group flexible-dose forced titration design. 100 eligible subjects with Fragile X Syndrome age 32 months to 6 years will enter a 4-month single-blind placebo lead-in period, followed by an 8-month double-blind treatment period during which subjects will randomized 1:1 to AFQ056 or placebo and will receive 6 months of language intervention. Subjects will then be invited to participate in an open-label extension phase during which all participants will receive treatment with active drug and continue language intervention for up to 8 months.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 110}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-08-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-09', 'completionDateStruct': {'date': '2022-05-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-09-15', 'studyFirstSubmitDate': '2016-09-28', 'resultsFirstSubmitDate': '2023-06-09', 'studyFirstSubmitQcDate': '2016-09-28', 'lastUpdatePostDateStruct': {'date': '2023-10-10', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-09-15', 'studyFirstPostDateStruct': {'date': '2016-09-30', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2023-10-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-05-17', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Weighted Child Intentional Communication Score', 'timeFrame': 'Baseline through Month 8', 'description': 'The Weighted Child Intentional Communication Score is derived from a 22 minute semi-structured examiner/child play session. Structured and unstructured component scores are found by multiplying each intentional communication act by the following weights: nonverbal = 1; single symbol = 2; and multiple symbols = 3. The two scores are summed together to obtain the total. Higher scores indicate more child-initiated communication. There is no maximum score.\n\nThe scale was administered at Baseline, Month 2, Month 4, Month 6, and Month 8. A composite score representing the average of the estimated change scores calculated at months 2, 4, 6, and 8 was recorded. A higher least squares mean value indicates a greater increase in WCS score from baseline.'}], 'secondaryOutcomes': [{'measure': 'Change in Mullen Scales of Early Learning (MSEL) Developmental Quotient (DQ)', 'timeFrame': 'Baseline through Month 8', 'description': 'Mullen Scales of Early Learning (MSEL) Developmental Quotient (DQ) is calculated by averaging the developmental age equivalents from 4 domains of the Mullen (visual reception, fine motor, receptive language, and expressive language) to find developmental age in months, dividing by chronological age in months, then multiplying by 100. DQ can range from 1 to 70. A higher DQ indicates better performance on the MSEL.\n\nThe MSEL was administered at Baseline, Month 2, and Month 8. A composite score representing the average of the estimated change scores calculated at month 2 and month 8 was recorded. A negative least squares mean indicates a net decrease in DQs over time. A more negative least squares mean indicates a larger negative change in DQs over time.'}, {'measure': 'Change in Mullen Scales of Early Learning (MSEL) Expressive Language Subscore', 'timeFrame': 'Baseline through Month 8', 'description': 'The MSEL measures performance over 5 subscales including expressive language. The range of possible subscores for the expressive language domain is 1-50. A higher score indicates better performance / greater use of expressive language\n\nThe MSEL was administered at Baseline, Month 2, and Month 8. A composite score representing the average of the estimated change scores calculated at month 2 and month 8 was recorded. A positive least squares mean indicates a net positive change in expressive language scores over time. A higher least squares mean indicates a larger change in expressive language scores over time.'}, {'measure': 'Change in Vineland Adaptive Behavior Scale (Vineland-3) Composite Score', 'timeFrame': 'Baseline through Month 8', 'description': "The Vineland-3 composite score is yielded from the subject's level of adaptive functioning in the domains of communication, daily living skills, socialization, and motor skills. The range of possible composite scores is 20-140 with a higher score indicating higher levels of adaptive functioning.\n\nThe Vineland-3 was administered at Baseline, Month 2, Month 4, Month 6, and Month 8. A composite score representing the average of the estimated change scores calculated at months 2, 4, 6, and 8 was recorded. A positive least squares mean indicates a net increase in composite score over time. A higher least squares mean indicates a greater change in composite score over time."}, {'measure': 'Change in Vineland Adaptive Behavior Scale (Vineland-3) Communication Subscore', 'timeFrame': 'Baseline and Month 8', 'description': 'The communication domain of the Vineland-3 examines adaptive functioning in receptive, expressive, and written language. The range of possible subscores for the communication domain is 20-140 with a higher score indicating more advanced use of language.\n\nThe Vineland-3 was administered at Baseline, Month 2, Month 4, Month 6, and Month 8. A composite score representing the average of the estimated change scores calculated at months 2, 4, 6, and 8 was recorded. A positive least squares mean indicates a net increase in communication score over time. A higher least squares mean indicates a greater change in communication score over time.'}, {'measure': 'Change in Preschool Language Scale (PLS-5) Expressive Communication Score', 'timeFrame': 'Baseline and Month 8', 'description': 'The PLS-5 is a comprehensive developmental language assessment that requires the child to point to or verbally respond to items. Raw scores for expressive language were collected from this test. It is difficult to specify an upper bound on the score, because there is no clear expectation of a limit on the number of times a child can communicate unless one sets it artificially (e.g., once per second in an 11-minute free play). The lower bound is zero for a child who produces no communication acts.\n\nThe PLS-5 was administered at Baseline, Month 2, and Month 8. A composite score representing the average of the estimated change scores calculated at month 2 and month 8 was recorded. A higher least squares mean indicates a larger change in PLS-5 communication score over 8 months.'}, {'measure': 'MacArthur-Bates Communicative Development Inventory (CDI) Number of Spoken Words', 'timeFrame': 'Month 8', 'description': 'The MacArthur-Bates CDI is a parent interview that allows tracking of a child\'s progress in developing words, sentences, and more complex language. The assessment consists of two parts including "Words Children Use," a 680-word vocabulary checklist in which the parent indicates those vocabulary words the child regularly produces in spoken language, and "Sentences and Grammar" an assessment of several aspects of grammar and word endings. The MacArthur-Bates CDI number of spoken words will be recorded with higher scores indicating more words used / greater language development at Month 8.'}, {'measure': 'Number of Participants With a Positive Response as Defined by Improvement in Clinical Global Impression - Improvement (CGI-I) Overall Function Scores', 'timeFrame': 'Month 8', 'description': "Completion of the CGI-I requires the clinician to rate how much the study participant's illness has improved or worsened relative to a baseline state. For this study, two sets of CGI-I are administered at each applicable visit - one associated with Language/Communication and the other to Overall Function. The Overall Function CGI-I considers all areas of function including cognition, adaptive behavior, and maladaptive behavior. The CGI-I is a 7-point scale that includes the following ratings: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.\n\nThe CGI-I was rated at all study visits after screening. This measure shows the number of participants with positive CGI-I scores indicating perceived improvement at Month 8."}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Fragile X Syndrome']}, 'referencesModule': {'references': [{'pmid': '39483619', 'type': 'DERIVED', 'citation': 'Protic D, Breeze E, Mendoza G, Zafarullah M, Abbeduto L, Hagerman R, Coffey C, Cudkowicz M, Durbin-Johnson B, Ashwood P, Berry-Kravis E, Erickson CA, Filipink R, Gropman A, Lehwald L, Maxwell-Horn A, Morris S, Bennett AP, Prock L, Talboy A, Tartaglia N, Veenstra-VanderWeele J, Tassone F. Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome. SAGE Open Med. 2024 Sep 29;12:20503121241282401. doi: 10.1177/20503121241282401. eCollection 2024.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS).', 'detailedDescription': 'This study will enroll 100 participants with Fragile X syndrome (FXS) between the ages of 32 months and 6 years.\n\nAfter being informed about the study and its potential risks, patients with Fragile X Syndrome will be screened for eligibility. Participants who meet entry criteria and agree to participate will then enter a single-blind 4-month placebo lead-in during which study participants will continue therapy treatments as usual to allow for placebo effects to stabilize. At the end of the 4-month placebo lead-in, all participants will have a repeat battery of AFQ056 baseline assessments and will enter the placebo-controlled phase, where they will be randomized in a 1:1 ratio to AFQ056 or placebo. All subjects will begin at a dose of 25 mg of AFQ056 or placebo, taken orally twice per day. Over 7 weeks, they will titrate up to their maximum tolerated dose (MTD), up to 100 mg. Once they have reached their MTD, both participant groups will initiate an intensive language intervention designed to maximize the extent to which parents engage in types of verbally responsive interactions that have been well documented as facilitating language learning. The entire language intervention will be delivered to the parent in the home or at scheduled study visits through the use of a laptop computer equipped with distance video-teleconferencing software and will include coaching, homework, and feedback sessions. Subjects will be treated with their MTD in combination with the language intervention for 6 months.\n\nAfter 8 months of treatment in the placebo-controlled phase (including 6 months of language intervention), all participants will have final assessments and will be given the opportunity to enter the open label extension (OLE) period. In the OLE, all participants will be treated with active drug according to the same schedule as in the placebo-controlled phase with 2 months of flexible dose titration to the MTD followed by a period of stable treatment, and will continue the language intervention throughout. A post-intervention follow-up visit will be conducted one month after the final assessment visit of the trial.\n\nResearchers will compare overall weighted communication score in the AFQ056 and placebo groups, after 6 months of treatment in combination with an intensive standardized parent-implemented language learning intervention. This is meant to serve as a marker of drug effect on neural plasticity, the core problem in the disorder. Further assessments will also be compared between groups to determine changes in language, cognitive, and adaptive functioning.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '6 Years', 'minimumAge': '32 Months', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria\n\n1. Age 32 months to 6 years inclusive at Screening (visit 1).\n2. Has an FMR1 full mutation.\n\n \\*\\*Note Presence of mosaicism is allowed\n3. DQ\\<75 calculated from the Mullen Scales of Early Learning at time of screening.\n4. Parent or legal guardian is available and able to communicate well with the investigator, comply with study requirements and provide written informed consent.\n\n \\*\\*Note\\*\\*The Parent or legal guardian who will be signing consent form, should be the individual administering the language intervention\n5. English is the primary language spoken in the home and the subject's first language is English.\n6. Meet criteria indicating evidence of intentional communication based on parent interview via a communication eligibility screening tool.\n\n \\*\\*Note\\*\\* On the Eligibility Screening Tool - Communication, the child must have at time of screening:\n 1. Section 1: Answer of YES; the child uses at least 5 spoken words to label items on a daily basis.\n\n OR\n 2. Section 2: At least 3 YES answers to items 1-10 if child does not have at least 5 spoken words.\n7. Produces 3 or more intentional acts of communication on the structured portion of the Weighted Communication play sample at time of screening.\n\n \\*\\*Note: subjects are permitted to use augmentative communication devices throughout the study if the device is the subject's primary form of communication and the device has been prescribed for the subject by an SLP.\n8. Stable behavioral and other therapy regimen for 30 days prior to screening.\n\n \\*\\*Note: Patients will be allowed to continue their standard of care therapies throughout the trial but these will not be changed during the placebo lead in or placebo controlled portion of the trial, outside of the standard changes occurring from school schedules.\n9. Stable dosing of all concurrent psychotropic medications except stimulants for at least 60 days prior to screening. Due to the very short half-life of stimulants (specifically methylphenidate and amphetamine variants), a stable regimen of these medications is required for 2 weeks only.\n\n * Note\\*\\* Medications impacting GABA, glutamate and/or mGluR5 pathway receptors are exclusionary and not permitted during study participation. Additionally, stimulant regimens may include combinations of short- and long-acting forms and may be taken with different timing or dosing on different days of the week (e.g. Doses may be skipped on weekends or days off school and extra doses may be given some days for therapy sessions later in the day). The intent is to keep the doses and regimen being used at the time of screening consistent during the trial even if there is some variation in how the medication is taken on different days.Use of CBD oil or hemp based substances legal for sale over the internet are allowed provided that the dosing regimen has been consistent for at least 60 days prior to screening and will remain the same throughout the trial.\n\nExclusion Criteria\n\n1. Use of medications impacting GABA, glutamate and/or mGluR5 pathway receptors or transmission.\n\n * Note\\*\\* Treatment with acamprosate, amantadine, budipine, carbetocin, cycloserine, dextromethorphan, felbamate, ketamine, lithium, minocycline, memantine, oxytocin, remacemide, racemic baclofen, riluzole, fycampa, investigational mGluR5 medications, and/or statins are exclusionary.\n * Note\\*\\* Lithium taken as a dietary supplement is permitted if the dose is less than 5mg/day. A 5mg/day dose is the recommended dietary intake level, and therefore is not considered to be therapeutic. Lithium dosage must remain the same throughout the duration of the trial and documented in the concomitant medication log.\n2. Unstable seizure disorder as defined by any seizure in the 6 months prior to the screening visit, and/or any change in anti-convulsant drug dosing in the 60 days prior to screening.\n\n \\*\\*Note\\*\\* Use of levetiracetam and oxcarbazepine are among permitted anticonvulsants.\n3. Use of any other investigational drug at the time of enrollment or within 30 days or 5 half-lives (whichever is longer) of the investigational drug prior to screening until end of study visits (or longer if required by local regulations).\n4. History of hypersensitivity to AFQ056 or any mGluR antagonist.\n5. History or presence of any clinically significant disease of any major system organ class, within the past 2 years prior to screening including but not limited to neurological, cardiovascular, endocrine, metabolic, renal, or gastrointestinal disorders. This does not include typical features of FXS such as psychological symptoms or history of epileptic seizures.\n6. Significant acute illness that did not completely resolve at least four weeks prior to the Screening visit.\n7. Abnormal laboratory values at screening that are in the opinion of the investigator are clinically significant and may jeopardize the safety of the study subject.\n8. Use of (or use within at least 5 half-lives before dosing) concomitant medications that are strong/moderate inhibitors or inducers of CYP1A1/2, CYP2C9/19 or CYP3A4 (see Appendix B).\n9. Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.\n10. Presence of immunodeficiency diseases at the time of screening, based on medical history, including a positive HIV test result.\n11. History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C result at time of screening.\n12. History or presence of suicidal thoughts and/or suicide attempts."}, 'identificationModule': {'nctId': 'NCT02920892', 'acronym': 'FX-LEARN', 'briefTitle': 'AFQ056 for Language Learning in Children With FXS', 'organization': {'class': 'OTHER', 'fullName': 'Rush University Medical Center'}, 'officialTitle': 'Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)', 'orgStudyIdInfo': {'id': 'ORA 15060903'}, 'secondaryIdInfos': [{'id': '1U01NS096767-01', 'link': 'https://reporter.nih.gov/quickSearch/1U01NS096767-01', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Double-Blind AFQ056 with language intervention', 'description': 'After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive AFQ056 suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, subjects in the AFQ056 treatment group began with a dose of 25 mg AFQ056 twice per day and titrated to their maximum tolerated dose over the course of 7 weeks. After 7 weeks the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on a stable dose of AFQ056 (ranging from 12.5 mg BID to 100 mg BID), for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.', 'interventionNames': ['Drug: AFQ056', 'Other: Language Intervention']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Double-Blind Placebo with language intervention', 'description': 'After a 4-month single-blind placebo lead-in period, subjects with FXS were randomized to receive a placebo suspension by mouth twice per day in an 8 month double-blind treatment period.\n\nDuring the double-blind treatment period, dose titration to maximum tolerated dose of matching placebo occurred over 7 weeks. After 7 weeks, the dose was fixed, and at the 2 month visit, the intensive language intervention was initiated. Subjects continued the language intervention while remaining on placebo for the next 6 months.\n\nSafety and efficacy assessments were performed throughout.', 'interventionNames': ['Drug: Placebo', 'Other: Language Intervention']}, {'type': 'EXPERIMENTAL', 'label': 'Open-Label AFQ056 with language intervention', 'description': "After 8 months of treatment in the placebo-controlled phase, all subjects had assessments completed and were given the opportunity to enter the open-label extension (OLE) in which all subjects received AFQ056. The OLE began with 2 months of flexible dose titration to each subject's maximum tolerated dose followed by a period of stable treatment. Subjects also continued the language intervention through the extension phase.\n\nThe duration of the stable treatment depended on when the subject was enrolled into the study. Those enrolled prior to June 15-30, 2019 received a 6-month period of stable treatment. Those enrolled after June 15, 2019 had their period of stable treatment shortened on a sliding scale, such that their treatment including weaning, if necessary, ended before August 31, 2021 (study drug expiration).", 'interventionNames': ['Drug: AFQ056', 'Other: Language Intervention']}], 'interventions': [{'name': 'AFQ056', 'type': 'DRUG', 'otherNames': ['Mavoglurant'], 'description': '12.5 mg - 100 mg oral suspension (liquid)', 'armGroupLabels': ['Double-Blind AFQ056 with language intervention', 'Open-Label AFQ056 with language intervention']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo oral suspension (liquid)', 'armGroupLabels': ['Double-Blind Placebo with language intervention']}, {'name': 'Language Intervention', 'type': 'OTHER', 'description': 'All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.\n\nThe language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.\n\nThe language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.', 'armGroupLabels': ['Double-Blind AFQ056 with language intervention', 'Double-Blind Placebo with language intervention', 'Open-Label AFQ056 with language intervention']}]}, 'contactsLocationsModule': {'locations': [{'zip': '95817', 'city': 'Davis', 'state': 'California', 'country': 'United States', 'facility': 'Univeristy of California - Davis', 'geoPoint': {'lat': 38.54491, 'lon': -121.74052}}, {'zip': '80045', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': "Children's Hospital of Colorado", 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '06520', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale University', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '20010', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': "Children's National Medical Center", 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '30033', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Emory University', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Boston Children's Hospital", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': "St Louis Children's Hospital (Washington University School of Medicine)", 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '10605', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Columbia University - New York Presbyterian', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '45229', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': "Cincinnati Children's Hospital Medical Center", 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43205', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': "Nationwide Children's Hospital", 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "Children's Hospital of Philadelphia", 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15213', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "Children's Hospital of Pittsburgh", 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt University Medical Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}], 'overallOfficials': [{'name': 'Elizabeth Berry-Kravis, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Rush University Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Elizabeth Berry-Kravis', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'class': 'NIH'}, {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Professor of Pediatrics, Neurological Sciences, Biochemistry', 'investigatorFullName': 'Elizabeth Berry-Kravis', 'investigatorAffiliation': 'Rush University Medical Center'}}}}